Verastem (VSTM) to Release Earnings on Thursday

Verastem (NASDAQ:VSTM - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Verastem to post earnings of ($0.65) per share and revenue of $0.10 million for the quarter.

Verastem (NASDAQ:VSTM - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.57). On average, analysts expect Verastem to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verastem Price Performance

NASDAQ VSTM opened at $7.49 on Thursday. The company has a market capitalization of $385.66 million, a PE ratio of -2.35 and a beta of 0.57. The company has a debt-to-equity ratio of 2.77, a quick ratio of 3.23 and a current ratio of 3.23. The business's fifty day moving average is $6.15 and its 200 day moving average is $5.26. Verastem has a fifty-two week low of $2.10 and a fifty-two week high of $13.52.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Guggenheim lifted their target price on Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research report on Monday, March 24th. StockNews.com downgraded Verastem from a "hold" rating to a "sell" rating in a research report on Friday, April 18th. Royal Bank of Canada cut their target price on Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday, March 21st. Mizuho lowered their price target on Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, Jefferies Financial Group assumed coverage on Verastem in a research note on Thursday, April 10th. They issued a "buy" rating and a $15.00 price target for the company. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $13.89.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.